DAFNA Capital Management’s Regulus Therapeutics RGLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-847,176
| Closed | -$1.48M | – | 79 |
|
|
2025
Q1 | $1.48M | Sell |
847,176
-28,024
| -3% | -$37K | 0.42% | 44 |
|
|
2024
Q4 | $1.38M | Sell |
875,200
-20,000
| -2% | -$30.7K | 0.35% | 49 |
|
|
2024
Q3 | $1.41M | Hold |
895,200
| – | – | 0.33% | 56 |
|
|
2024
Q2 | $1.6M | Sell |
895,200
-175,348
| -16% | -$407K | 0.38% | 48 |
|
|
2024
Q1 | $3.08M | Sell |
1,070,548
-40,501
| -4% | -$66K | 0.7% | 35 |
|
|
2023
Q4 | $1.42M | Hold |
1,111,049
| – | – | 0.34% | 53 |
|
|
2023
Q3 | $1.52M | Hold |
1,111,049
| – | – | 0.47% | 43 |
|
|
2023
Q2 | $1.63M | Buy |
1,111,049
+555,494
| +100% | +$740K | 0.45% | 43 |
|
|
2023
Q1 | $471K | Hold |
555,555
| – | – | 0.14% | 61 |
|
|
2022
Q4 | $761K | Hold |
555,555
| – | – | 0.21% | 57 |
|
|
2022
Q3 | $944K | Hold |
555,555
| – | – | 0.25% | 60 |
|
|
2022
Q2 | $1.15M | Sell |
555,555
-1
| -0% | -$2 | 0.31% | 60 |
|
|
2022
Q1 | $1.66M | Hold |
555,556
| – | – | 0.43% | 57 |
|
|
2021
Q4 | $1.75M | Buy |
+555,556
| New | +$2.47M | 0.44% | 48 |
|
|
2016
Q4 | – | Sell |
-3,513
| Closed | -$1.39M | – | 72 |
|
|
2016
Q3 | $1.39M | Hold |
3,513
| – | – | 0.97% | 37 |
|
|
2016
Q2 | $1.22M | Buy |
3,513
+250
| +8% | +$179K | 0.97% | 36 |
|
|
2016
Q1 | $2.71M | Buy |
3,263
+2,513
| +335% | +$2M | 2.34% | 14 |
|
|
2015
Q4 | $785K | Hold |
750
| – | – | 0.7% | 40 |
|
|
2015
Q3 | $589K | Buy |
+750
| New | +$770K | 0.58% | 45 |
|
Other funds holding RGLS
DAFNA Capital Management's RGLS Position: Q2 2025 in Review
DAFNA Capital Management sold out of Regulus Therapeutics (RGLS) in Q2 2025, closing a stake of 847,176 shares — an estimated $1.48M sold.
DAFNA Capital Management first reported a position in RGLS in Q3 2015 and held it in 19 quarters. The position peaked at $3.08M in Q1 2024. 0 funds tracked by Wall St. Rank hold RGLS as of Q2 2025.
- DAFNA Capital Management reported no remaining Regulus Therapeutics position as of Q2 2025 after selling out during the quarter.
- DAFNA Capital Management sold 847,176 Regulus Therapeutics shares in Q2 2025, an estimated $1.48M.
- DAFNA Capital Management first reported a position in Regulus Therapeutics in Q3 2015 and held it in 19 quarters.
- DAFNA Capital Management's Regulus Therapeutics position peaked at $3.08M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2025.
Based on DAFNA Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.